0000000000848493

AUTHOR

Jeff S. Healey

showing 2 related works from this author

Antiplatelet therapy in patients with atrial fibrillation: a systematic review and meta-analysis of randomized trials.

2021

Abstract Aims  The aim of this study was to systematically assess the effects of antiplatelets on clinical outcomes in patients with atrial fibrillation (AF), treated and not-treated with oral anticoagulation. Methods and results  We searched MEDLINE, Embase, and CENTRAL from inception until September 2020. From 5446 citations, we selected randomized trials allocating patients with AF to antiplatelet therapy vs. control. We applied random-effects models for meta-analysis and assessed potential effect modification with background anticoagulation use. Eighteen trials including 21 518 participants met our prespecified eligibility criteria. In 10 studies without background anticoagulation, anti…

medicine.medical_specialtyMEDLINEMyocardial InfarctionHemorrhage030204 cardiovascular system & hematologylaw.inventionBrain Ischemia03 medical and health sciences0302 clinical medicineRandomized controlled triallawInternal medicineAtrial FibrillationMedicineHumansPharmacology (medical)030212 general & internal medicineMyocardial infarctionStrokeRandomized Controlled Trials as TopicAspirinbusiness.industryAnticoagulantsAtrial fibrillationmedicine.diseaseConfidence interval3. Good healthStrokeRelative riskCardiology and Cardiovascular MedicinebusinessPlatelet Aggregation Inhibitorsmedicine.drugEuropean heart journal. Cardiovascular pharmacotherapy
researchProduct

Estimated stroke risk, yield, and number needed to screen for atrial fibrillation detected through single time screening: a multicountry patient-leve…

2019

Background The precise age distribution and calculated stroke risk of screen-detected atrial fibrillation (AF) is not known. Therefore, it is not possible to determine the number needed to screen (NNS) to identify one treatable new AF case (NNS-Rx) (i.e., Class-1 oral anticoagulation [OAC] treatment recommendation) in each age stratum. If the NNS-Rx is known for each age stratum, precise cost-effectiveness and sensitivity simulations can be performed based on the age distribution of the population/region to be screened. Such calculations are required by national authorities and organisations responsible for health system budgets to determine the best age cutoffs for screening programs and d…

MaleHealth ScreeningEconomicsSocial Sciences030204 cardiovascular system & hematologyVascular MedicineScreening programmeElectrocardiography0302 clinical medicineRisk FactorsHealth careAtrial FibrillationMedicine and Health SciencesMass ScreeningPublic and Occupational Health030212 general & internal medicinemedia_commonAged 80 and overRAge FactorsGeneral MedicineMiddle AgedUniversity hospitalPrognosis3. Good healthStrokeBioassays and Physiological AnalysisNeurologyHealthMedicineFemaleTraining programArrhythmiaResearch ArticleAdultCerebrovascular DiseasesCost-Effectiveness AnalysisCardiologyLibrary scienceResearch and Analysis MethodsRisk AssessmentStroke risk03 medical and health sciencesYoung AdultAge DistributionSex FactorsPopulation MetricsPredictive Value of TestsPolitical sciencemedia_common.cataloged_instanceHumansEarly careerEuropean unionIschemic StrokeAgedHealth Care PolicyPopulation Biologybusiness.industryElectrophysiological TechniquesBiology and Life SciencesNumber needed to screenEconomic AnalysisHealth CareAge GroupsPeople and PlaceseHealthPopulation GroupingsCardiac ElectrophysiologybusinessScreening Guidelines
researchProduct